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ABSTRACT
Immunized against hepatitis B virus (HBV) recipients are at risk of developing HBV postallogeneic stem cell
transplantation because of the potential loss of their HBV immunity. The aim of the study was to evaluate: (1)
the HbsAb eradication incidence posttransplant and potential risk factors, (2) the impact of donor’s immunity
on HbsAb loss, (3) the incidence of hepatitis B in patients with HbsAb disappearance. We studied, retrospec-
tively, in 26 vaccinated and 56 naturally immunized recipients, the posttransplant HbsAb titers for a median
period of 36 (6-132) months. The probability of HbsAb loss and HBV-related hepatitis was determined in all
recipients. The impact of donor’s immunity origin in the HBsAb disappearance was evaluated in the subgroup
of, actively or naturally, immunized recipients/donors pairs. The 5-year probability of HbsAb disappearance
was 90% for all patients with 18% probability of developing hepatitis at 12 years, for those who lost HbsAb.
Marrow graft, antithymocyte globulin administration, age <30 years and chronic graft-versus-host disease
were significant risk factors for HbsAb loss. In the subgroup of immunized recipients/donors, the donor’s
active immunization significantly affected this loss. Allotransplanted patients are at high risk of losing protec-
tion against HBV. The adoptive transfer of active HBV immunity does not seem to offer sustained protection
posttransplant.
© 2007 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
Hepatitis B virus (HBV) infection is one of the
ost common viral infections in humans. It is esti-
ated that more than 2 billion individuals worldwide
ave been exposed to HBV [1]. The acquisition of
BV immunity requires adequate B and T cell re-
ponses which, depending on the type of antigenic
timulation, lead to the production of protective anti-
odies such as surface (HbsAb) or core antibody (Hb-
Ab). Immunocompetent individuals are able to attain
mmunity against HBV either via direct exposure to
irus (natural immunity) or via vaccination (active im-
unity). HBV infection is a causative factor for seri-
us and sometimes fatal liver complications after al- Hogeneic stem cell transplantation (alloTx) [2,3].
atients who have undergone alloTx have a long-
asting impaired immunologic function, because of the
nderlying disease, previous chemotherapies, condi-
ioning regimens, donor type (sibling, relative, or un-
elated), graft versus host disease (GVHD), immuno-
uppressive prophylaxis or GVHD treatment. Because
f this, they are at high risk of losing either their
reviously acquired immunity or the adoptive immu-
ity transferred from an immunized donor [4-10].
hus, these patients are candidates for an overt or
atent HBV infection either as a result of virus reac-
ivation or because of a direct virus transfer through
lood product infusions. To determine the rate of
bsAb disappearance post-alloTx and deﬁne risk fac-
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P. Kaloyannidis et al.1050ors for this loss, we studied the HbsAb titers post-
ransplant, in actively or naturally immunized recipi-
nts, and we evaluated the contribution of donor’s
mmunity to HbsAb titer alterations. In addition, we
etermined the incidence of HBV-related hepatitis in
hose patients who lost their previous immunity.
ATIENTS AND METHODS
nstitutional Review Board (IRB) Approval
We did not apply for an IRB approval, as our
RB’s policy is to review only prospective studies.
owever, all patients undergoing alloTx in our cen-
er, since 2000, are routinely asked to consent for
he anonymous use of their medical records in sci-
ntiﬁc registries or in retrospective studies by our
enter.
tudy Group
Eighty-two previously immunized against HBV
atients, who had consecutively (1991-2004) under-
one alloTx and had been followed for 36 (6-132)
onths postallografting were studied retrospectively
n terms of humoral HBV immunity. Patients trans-
lanted in the same study period but negative for
bsAb, HbcAb, or HbeAb were excluded from the
tudy because of the lack of evidence of HBV immu-
ity. The median age of the recipients was 27 (11-54)
ears. Twenty-six had obtained their immunity by
accination, and this was indicated by their medical
istory and the presence of HbsAb only, without ev-
dence of HbcAb or HbeAb. Fifty-six recipients were
aturally immunized after a previous occult HBV in-
ection, as it was implied by positive HbsAb plus
bcAb. All patients received ablative conditioning
Busulfan or total-body irradiation [TBI] plus Cyclo-
hosphamide) except one, who received a reduced
ntensity (ﬂudarabine-based) regimen. GVHD pro-
hylaxis consisted of a combination of cyclosporine or
acrolimus plus short-term methotrexate (MTX) for
hose patients who received myeloablative regimen,
hereas cyclosporine plus mycophenolate mofetil
MMF) was administered to the patient who was al-
ografted with a reduced-intensity (RIC) regimen. Six-
y-eight donors were identical siblings, 4 were siblings
ith 1 antigen mismatch, 7 were matched unrelated
olunteers (MUD), 2 were twins, and 1 was hap-
oidentical. Twenty-three patients received a marrow
raft, 58 peripheral blood stem cells (PBSC) after
ranulocyte colony stimulating factor (G-CSF) (ﬁl-
rastim or lenograstim) priming, and 1 bone marrow
lus PBSC. No ex vivo graft manipulations were per-
ormed. A median number of 4.45  106/kg CD34,
.77  108/kg CD3, 1.16  108/kg CD4 and 1.06
108/kg CD8 cells were infused. Acute and chronic
VHD (aGVHD, cGVHD) was developed in 30 of2 and 71 of 82 patients, respectively. All patients
eceived intravenously multipotent gamma globulins
nd acyclovir or valacyclovir for at least 6 months in
he postgrafting period. No patient received speciﬁc
BV prophylaxis (anti-HBV immunoglobulins or
amivudine). Antithymocyte globulin (ATG) was ad-
inistered in 15 of 82 patients either during the con-
itioning regimen or as treatment for refractory
VHD, whereas 54 patients received corticosteroids.
one of the patients received additional lymphocyte
r other cell infusions for any reason during the study
eriod.
able 1. Patients Characteristics
ex: Male/Female 53/29
edian Age (years) 27 (range: 11-54)
edian follow up (months) 36 (range: 6-132)
iagnosis
AML 38
ALL 18
NHL 10
CML 9
Aplastic anemia 4
Thalassemia 2
MDS 1
onditioning regimen
Busulfan 16mg/kr or TBI 14,4 Gy
plus Cyclophosphamide 120mg/kg 81
Fludarabine 150mg/m2 plus
Busulfan 8mg/Kg 1
raft source
Marrow 23
PBSC 58
Marrow plus PBSC 1
nfused cells
Median number CD34 (106/kg) 4,45 (range: 0,6-23,4)
Median number CD3 (108/kg) 2,77 (range: 0,06-10)
Median number CD4 (108/kg) 1,16 (range: 0,03-4,91)
Median number CD8 (108/kg) 1,06 (range: 0,01-5,53)
LA-compatibility
Siblings 68
Siblings with 1antigen mismatched 4
MUD 7
Twin 2
Haploidendical 1
vHD prophylaxis
Cyclosporine or tacrolimus plus
Methotrexate 81
Cyclosporine plus Mycophenolate
Mofetil 1
TG administration 15
teroids administration 54
cute GvHD 30
hronic GvHD extensive 71
ecipients’ immunity
Vaccination 26
Natural 56
onors’ immunity
Non–immunized 46
Vaccination 19
Natural 13
Unknown type of immunity 4
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HbsAb Disappearance Postallografting 1051Forty-six donors were nonimmunized and 36 were
mmunized against HBV. With respect to donors’
ype of immunity, 19 had been vaccinated and 13 had
atural immunity, whereas the immunity origin was
nknown in 4 donors (Table 1).
erologic Testing
All patients were serially tested every 3 months
ost-alloTx for their HBV immunity status. Serologic
xaminations for HBV surface antigen (HbsAg),
bsAb, HbcAb, and HbeAb were performed using the
LISA assay (Abbott, Irving, TX) according to the
anufacturer’s instructions. The median HbsAb titer
realloTx, for naturally immunized patients was 89
15-1000) IU/mL and for actively immunized 100
20-1000) IU/mL. We focused on the ﬂuctuations of
bsAb’s titers posttransplant in previously immu-
ized patients against HBV, as HbsAb represents the
trongest marker for HBV immunity. Although
bsAb titers lower than 10 IU/mL are widely consid-
red as nonprotective against HBV, we deﬁned as loss
f HBV immunity, only the undetectable levels of
bsAb.
During the study period no vaccination against
BV was applied post-alloTx, as there were no stan-
ard vaccination recommendations in stem cell trans-
lant recipients until recently. Our current strategy, in
ompliance with the recent guidelines on vaccination
igure 1. Decrease of HbsAb titers post-alloTx. Box plots showing
ach time point is shown above boxes. The thick line inside the red
5th and 75th percentiles.ost-alloTx [11], is to vaccinate all allografted patients
f they have unprotective HbsAb titers.
tatistical Analysis
Statistical analyses were performed using the Sta-
istical Program for Social Sciences (SPSS 9.0 for
indows). The Kaplan-Meier method was used for
alculation of the cumulative probability of HbsAb
isappearance for the total cohort of patients and for
ransplanted patients from immunized donors. The
ame method was also used for the calculation of the
umulative probability of HBV infection and HBV
everse seroconversion. A Cox regression analysis was
sed to determine possible factors that inﬂuence the
bsAb disappearance postallografting. Factors that
ffect the loss of immunity or contribute to immuno-
ompetence postallogeneic transplant were incorpo-
ated as categoric variables in the multivariate model.
hese factors were age, number of CD34, CD3,
D4, and CD8 infused cells, source of the graft,
GVHD presence, administration of ATG and ste-
oids. To investigate whether recipient’s and donor’s
mmunity affects HbsAb disappearance as an indepen-
ent factor we also incorporated the type of recipient-
onor immunity in the Cox regression model. As all
llografted patients from mismatched or unrelated do-
ors received ATG, we did not test the recipient-
e-depended HbsAb decrease. Number (n) of evaluated patients at
epresents the median titer value. The ends of the boxes deﬁne thethe tim
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P. Kaloyannidis et al.1052onor compatibility as a separate variable. Statistical
igniﬁcance was deﬁned as a P value .05 (2-tailed).
ESULTS
bsAb Disappearance in All Patients
A progressive decrease in HbsAb titers started
fter the ﬁrst quarter post-alloTx with 3 patients hav-
ng undetectable levels of HbsAb at 6 months. Finally,
9 (11 with previous active and 28 with previous
atural immunity) of 82 (47%) patients gradually lost
heir HBV immunity (Figure 1). The median time for
bsAb negativity was 36 (6-60) months, with a loss
robability of 90% at 5 years (Figure 2). All patients
ere at stable donor chimerism and in complete re-
ission at the time of HbsAb disappearance. In a
ultivariate analysis, age 30 years, marrow graft,
GVHD presence, and ATG administration were
emonstrated as signiﬁcant factors for the loss of
BV immunity.
bsAb Disappearance According
o Donor’s Immunity
In all patients the presence and the type of donors’
mmunity did not signiﬁcantly inﬂuence HbsAb neg-
tivity in the multivariate Cox regression analysis
Table 2). The probability of losing previous HBV
mmunity was 100% for patients who received grafts
rom nonimmunized donors versus 78% for those
ho received grafts from vaccinated donors versus
8% for those allografted from naturally immu-
ized donors. To evaluate the adoptive transfer of
BV immunity, a well-described phenomenon in
he literature [8-10,12-14] we separately studied pos-
ible risk factors for HbsAb disappearance in 36 pa-
ients who allografted from actively or naturally im-
unized donors. The marrow graft and ATG
dministration retained their signiﬁcance in this co-sFigure 2. Probability of HbsAb disappearance post-alloTx.ort of patients and the active versus natural donor’s
mmunity proved to be a favorable signiﬁcant factor
or HbsAb negativity. The use of steroids had a strong
endency towards signiﬁcance (P .06) (Table 3).
BV Infection Post-HbSAb Disappearance
Although the primary aim of this study was to
valuate the HBV immunity status post-alloTx, we
lso examined the HBV infection incidence post-Hb-
Ab disappearance. Six of 39 patients (15%), all with
revious natural immunity and sustained seronegative
able 2. Multivariate Analysis (Cox Regression) of Potential Risk
actors for HbsAb Disappearance in All Patients
Risk Factor
Patients
(N  82)
Patients with
Loss of
HbsAb (%)
Significance
(P Value)
ge
<30 years 50 27 (54%)
>30 years 32 12 (33%) .05
D34*
>4.45  106/kg 41 16 (39%)
<4.45  106/kg 41 23 (56%) .9
D3*
>2.27  108/kg 41 14 (34%)
<2.27  108/kg 41 25 (60%) .4
D4*†
>1.16  108/kg 34 12 (35%)
<1.16  108/kg 34 15 (44%) .09
D8*†
>1.06  108/kg 33 12 (36%)
<1.06  108/kg 34 15 (44%) .41
GVHD
Yes 71 35 (49%)
No 11 4 (36%) .05
se of steroids
Yes 54 28 (52%)
No 28 11 (35%) .23
se of ATG
Yes 15 9 (60%)
No 67 30 (45%) .01
raft
Marrow 23 16 (70%)
Peripheral blood** 59 23 (39%) .04
ype of recipient’s
immunity
Vaccination 26 11 (42%)
Natural 56 28 (50%) .18
ype of donor’s
immunity
No immunity 46 24 (52%)
Vaccination 19 8 (42%)
Natural 13 5 (31%)
Unknown type of
immunity 4 2 .79
GVHD indicates chronic graft-versus-host disease; ATG, antithy-
mocyte globulin; PBSC, peripheral blood stem cells.
The median value of infused CD34, CD3, CD4, and CD8
cells was selected as the cutoff for comparison.
Data for CD4 and CD8 graft subpopulations were available of 68
and 67 patients, respectively.
*Including an allografted patient with bone marrow plus PBSC.tatus developed HBV infection. None of them had
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HbsAb Disappearance Postallografting 1053ny evidence of transmitted infection (ie, transfu-
ions). Consequently, hepatitis was attributed to HBV
eactivation, known as reverse seroconversion (RS).
our patients had received grafts from nonimmunized
onors and 2 from naturally immunized donors, and
ll had been treated or were on intensive therapy for
efractory cGVHD. The probability for RS in patients
ho lost HbsAb, regardless of immunity origin, was
8% at 12 years (Figure 3). More speciﬁcally, 6 of 28
21%) naturally immunized patients (with previous
bsAb plus HbcAb) who lost the HbsAb developed
able 3. Multivariate Analysis (Cox Regression) of Potential Risk
actors for HbsAb Disappearance in the Subgroup of Allografted
atients from Immunized Donors
Risk Factor
Patients
(N  36)
Patients with
Loss of
HbsAb (%)
Significance
(P Value)
ge
<30 years 21 10 (48%)
>30 years 15 5 (30%) .47
D34*
>4.45  106/kg 23 7 (30%)
<4.45  106/kg 13 8 (61%) .13
D3*
>2.27  108/kg 20 5 (25%)
<2.27  108/kg 16 10 (62%) .78
D4*†
>1.16  108/kg 17 4 (23%)
<1.16  108/kg 13 6 (46%) .99
D8*†
>1.06  108/kg 15 4 (27%)
<1.06  108/kg 14 6 (43%) .98
GVHD
Yes 31 13 (42%)
No 5 2 (40%) .11
se of steroids
Yes 19 9 (47%)
No 17 6 (35%) .06
se of ATG
Yes 7 6 (86%)
No 29 9 (31%) .01
raft
Marrow 8 6 (75%)
Peripheral blood** 28 9 (32%) .04
ype of recipient’s
immunity
Vaccination 13 8 (61%)
Natural 23 7 (30%) .18
ype of donor’s
immunity***
Vaccination 19 8 (42%)
Natural 13 5 (38%) .01
GVHD indicates chronic graft-versus-host disease; ATG, antithy-
mocyte globulin; PBSC, peripheral blood stem cells.
The median value of infused CD34, CD3, CD4, and CD8
cells, from the total study group (n  82), was selected as the
cutoff for comparison.
Data for CD4 and CD8 graft subpopulations were available of 30
and 29 patients, respectively.
*Including an allografted patient with bone marrow plus PBSC.
**There were no data on the type of immunity of 4 donors. cepatitis, raising the 12-year probability of RS at 26%
Figure 4).
ISCUSSION
The intensive immunosuppression aimed to over-
ome age or HLA compatibility barriers in the alloTx
etting may cause loss of HBV immunity and put
atients at an increased risk of HBV infection. Al-
hough a minority of patients ﬁnally develop severe
linical hepatitis or posttransplant liver disease, the
revention of HBV infection will reduce the trans-
lant-related morbidity and mortality and lead to im-
roved outcomes.
The presence of HbsAb is probably the most ac-
urate marker of HBV immunity. Existing informa-
igure 3. Probability of HBV infection post-HbsAb disappear-
nce.
igure 4. Probability of HBV-reverse seroconversion (HBV infec-
ion for patients with previous natural immunity: HbsAb and Hb-
Ab positive).
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P. Kaloyannidis et al.1054ion on HbsAb disappearance in the posttransplant
eriod is limited, and derived from series with either
mall number of patients or short-term follow-up [15-
9]. To our knowledge, the present study, which re-
orts 82 patients with a median follow-up of 36 (6-
32) months, is the largest series.
Consistent with previous published reports the
robability of HbsAb disappearance in our study was
0% at 5 years [16]. The maintenance of immunity
gainst HBV, as with other viruses, is strongly depen-
ent on the immune functional capacity post alloTx
20]. It seems that the loss of previous HBV immunity
s an inevitable and late-onset phenomenon occurring
s a result of the gradual loss of recipient’s immune
ells in combination with the prolonged inadequate
cell-dependent B cell responses [4-5,21]. We ob-
erved a delayed HbsAb disappearance after 6 months
ost-alloTx even in patients who received grafts from
onimmunized donors. This could be partially ex-
lained by the long lasting maintenance of recipients’
and memory cells [22].
Although PBSC grafts contain 4-10-fold more
ature lymphocytes than marrow grafts, it still re-
ains controversial whether the greater number of
ymphocytes in PBSC results in faster numeric and
unctional immune reconstitution [23,24]. Recently,
brahamsen et al. [6] published the results of a pro-
pective randomized study demonstrating that the
arly immune recovery is enhanced in PBSC com-
ared to marrow allografting. There are no clinical or
reclinical studies to assess whether the functional
apacity of lymphocytes upon stimulation with HBV
roteins is different between PBSC and marrow re-
ipients. In our study PBSC was a favorable factor for
BV immunity maintenance compared to marrow
raft. This ﬁnding could be interpreted as a result of
he higher number of lymphocyte subpopulations in
he PBSC graft.
It has not yet been clariﬁed whether the dose of
rogenitor stem cells correlates with the rapidity of
mmune reconstitution. It has been shown in a pre-
linical model and in a clinical study, that a higher
tem cell (CD34 cells) dose resulted in faster im-
une recovery [25,26], although in our study we
ould not demonstrate any association between the
bsAb disappearance and the infused stem cell dose.
In our study, patients aged 30 years had a higher
robability for HbsAb negativity. This is in contrast with
urrent knowledge that older patients have poorer ca-
acity for regeneration of the immune system [21,27,28].
possible interpretation for this ﬁnding could be the
ore intense immunosuppression, the younger patients
n our study, received in previous conventional treat-
ents. Twenty-three of 50 patients under 30 years
46%) had received 2 lines of therapy, whereas only 8
f 32 (25%) aged 30 years received multiple cycles of
hemotherapy before transplantation. icGVHD is one of the major factors for immune
ystem’s dysfunction in the posttransplant period. It
as been reported that cGVHD might result in earlier
isappearance of recipient-oriented IgG [22]. In a
ublished study of 14 previously immunized al-
ografted patients, the disappearance of HbsAb oc-
urred regardless of cGVHD presence [16], and this
as probably because of the small number of studied
atients. In contrast, our study of 82 allografted pa-
ients, demonstrated that cGVHD could represent an
ndependent signiﬁcant factor for HbsAb disappear-
nce.
Although the probability for HbsAb disappearance
t 5 years was 100% for those patients who received
teroids versus 80% for those who did not, this dif-
erence did not prove to be signiﬁcant. In contrast,
TG, which is a powerful immunosuppressive agent
ffecting T and B cell number and function and re-
ulting in long-lasting dysfunction of the immune sys-
em [29], not surprisingly, was raised as a signiﬁcant
actor for HbsAb disappearance.
Although the adoptive transfer of cellular but also
umoral immunity against HBV has been established
n preclinical models and in clinical studies [8-10,12-
4], so far, no comparative studies have been pub-
ished regarding the maintenance of HbsAb-positivity
ost-alloTx with respect to the type of donor’s immu-
ity. In our study, the 5-year probability of HbsAb
egativity was 100% for allografted patients from
onimmunized donors, whereas this probability was
8% for those allografted from vaccinated donors and
8% for allografted patients from naturally immu-
ized donors. These differences were not signiﬁcant
hen all patients were examined. Subsequently, we
eparately studied 36 patients who were allotrans-
lanted from vaccinated or naturally immunized do-
ors to investigate the impact of adoptive transfer of
BV immunity to HbsAb negativity post-alloTx. Do-
or’s immunity obtained via vaccination proved to be
favorable signiﬁcant factor for HBV negativity in
ontrast to natural obtained immunity. Consistent
ith this, it has been demonstrated that the adoptive
ransfer of natural immunity is more effective for the
bsAg clearance after hematopoietic stem cell trans-
lantation [30,31], probably because of the higher
requency of core antigen-speciﬁc CD4 and CD8
cells than the surface antigen-speciﬁc T cells in the
raft [13].
RS of hepatitis B is not a rare complication and
ay occur late (months to years) post-alloTx. In a
etrospective study of 37 patients, Dhédin et al. [18]
emonstrated that the actuarial risk of RS was 20.5%,
hereas the actuarial risks in published small series
idely range from 14% to 70%, and may underesti-
ate the risk of virus reactivation because of a short
ollow-up [16,18,19,32]. In our study, 6 (all naturally
mmunized) of 39 (actively or naturally immunized)
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HbsAb Disappearance Postallografting 1055atients with HbsAb eradication developed HBV in-
ection, reaching a probability of RS of 18% at 12
ears. Undoubtedly, patients with resolved HBV in-
ection and with gradual loss of HbsAb and HbcAb are
t higher risk of HBV reactivation because of the
ersistence of the virus in a “latent” state in the liver
nd in peripheral blood mononuclear cells [33]. In our
tudy, the subgroup of patients with loss of previous
atural immunity had a probability of RS of 26% at 12
ears. The small sample size did not allow us to per-
orm statistical analyses to determine possible risk
actors for RS in this high-risk subgroup.
In conclusion, it seems that the pretransplant
BV immunity will be lost in the majority of recipi-
nts regardless of adoptive immunity transfer. The
ate of HbsAb negativity remains high in the late
osttransplant period even after 5 years. As the possi-
ility of RS is not negligible, careful serial serologic
onitoring and an appropriate vaccination schedule
ith booster vaccinations for reimmunization in the
arly but also in the late posttransplant period, might
e necessary for patients with low or decreasing Hb-
Ab titers [11].
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